Iowa City, IANCT06756932Now EnrollingIRB Ready

Hormone-receptor-positive Breast Cancer Clinical Trial in Iowa City, IA

Access cutting-edge hormone-receptor-positive breast cancer treatment through this clinical trial at a research site in Iowa City. Study-provided care at no cost to qualified participants.

Sponsored by BeOne Medicines

Quick Self-Assessment

See if you qualify for this Iowa City location

Preparing your pre-screening questions…

Expert Care in Iowa City

Access hormone-receptor-positive breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hormone-receptor-positive breast cancer treatment provided free

Apply for This Iowa City Location

Check if you qualify for this hormone-receptor-positive breast cancer clinical trial in Iowa City, IA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Iowa City

    Convenient for IA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Iowa City site if eligible
  4. 4Begin participation

About This Hormone-receptor-positive Breast Cancer Study in Iowa City

This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.

Sponsor: BeOne Medicines

Who Can Participate

Inclusion Criteria

Histologically or cytologically confirmed HR+/HER2- metastatic breast cancer. Part 1A and 1B: Participants must have received ≥ 1 prior line(s) of treatment for advanced/metastatic disease, including prior endocrine therapy and CDK4/6 inhibitor in either the adjuvant or advanced/metastatic setting. Part 2: Participants must have received 1-3 prior line(s) of treatment for advanced/metastatic disease, including prior endocrine therapy and CDK4/6 inhibitor in either the adjuvant or advanced/metastatic setting.
Female participants will be required (either continue ongoing or initiate as soon as feasible) to have ovarian function suppression using gonadotropin-releasing hormone (GnRH) agonists (such as goserelin) or be postmenopausal.
Male participants may be required to use GnRH agonists when being treated with fulvestrant at the discretion of the investigator.
Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
Adequate organ function.
Female participants of childbearing potential and nonsterile male participants with female partners of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and for 7 days after the last dose of BGB-21447, 6 months after the last dose of BGB-43395, and 2 years after the last dose of fulvestrant.
Food effect substudy only: Participants who are able and willing to fast overnight (≥ 10 hours) and consume a high-fat meal.

Exclusion Criteria

Prior Bcl-2 inhibitor exposure. For triplet combination cohorts only: Prior therapy selectively targeting CDK4.
Known leptomeningeal disease or uncontrolled, untreated brain metastases.
Any malignancy ≤ 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, treated papillary thyroid carcinoma, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
For Part 1B: Uncontrolled diabetes.
History of hepatitis B or active Hepatitis C infection
China Only: Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers with HBV DNA \> 500 IU/ml (or \> 2500 copies/ml) at screening. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Iowa City?

Yes, this clinical trial (NCT06756932) has an active research site in Iowa City, IA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hormone-receptor-positive Breast Cancer Treatment Options in Iowa City, IA

If you're searching for hormone-receptor-positive breast cancer treatment options in Iowa City, IA, this clinical trial (NCT06756932) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Iowa City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hormone-receptor-positive breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hormone-receptor-positive breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Iowa City, IA

See all breast cancer clinical trials recruiting in Iowa City — not just this study.

Browse Breast Cancer Trials in Iowa City →

Browse More Trials by Condition

Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Iowa City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Iowa City, IA